Content by Twist Bioscience

Detection panels that enrich RNA transcripts help scientists achieve sensitive and relevant analyses of cancer-causing gene fusions.

Find answers to common synthetic biology research questions in this collection of quick educational videos.

Sequencing circulating tumor DNA (ctDNA) within liquid biopsies permits tumor identification and tracking. 

Scientists compared protein engineering with a synthetic library versus error-prone PCR to achieve better variant representation and simpler validation.

Discover how efforts to uncover the genome's methylation patterns advance cancer detection.

Discover tips and tricks to successfully perform custom CRISPR screens.

Researchers use long custom oligos to screen viral genome stability with an NGS workflow.

Enzymatic conversion and hybrid capture target enrichment combine to optimize methylation sequencing.

From identifying targets to testing lead candidates, developing antibodies into clinical therapies is a process full of twists and turns.

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Biotia, Inc., a company that uses proprietary analytical software for infectious disease diagnostics, today received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the SARS-CoV-2 Next-Generation Sequencing (NGS) Assay.

-- Studying Methylation Patterns Provides Unique Insight into Disease Pathology -- -- System Improves Accuracy of Results, Allows Capture of Customized Genes of Interest, Operational Efficiency --

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Biotia, Inc., a company that uses proprietary analytical software for infectious disease diagnostics, today announced the availability of an important new research tool for the sequencing and surveillance of COVID-19.